Health care startups that raised Series B in the United States
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| Prolific Machines | Emeryville | Series B | $50.0M | 2026-10-14 |
| Multiply Labs | San Francisco | Series B | $75.0M | 2026-10-06 |
| Tiny Health | Austin | Series B | $33.0M | 2026-09-29 |
| UltraSight | Cambridge | Series B | $24.0M | 2026-09-23 |
| Evvy | New York | Series B | $40.0M | 2026-09-15 |
| Vibronix | West Lafayette | Series B | $14.9M | 2026-09-14 |
| Moonwalk Biosciences | South San Francisco | Series B | $70.0M | 2026-09-08 |
| Superluminal Medicines | Boston | Series B | $65.5M | 2026-09-03 |
8 rows of the CSV in 5 of its 18 columns.
- The 1,286 health care startups in the United States whose last round is Series B have raised $73.8B in total.
- 134 of them closed their most recent round in the last 12 months, $7.6B combined.
- The largest of those rounds is Ollin Biosciences' $330.0M Series B, dated June 2026.
- The most recent is Rgenta Therapeutics' $41.9M Series B on 3 November 2026.
- Alumni Ventures is an investor in 16 of them, more than any other fund.
- Biotech is the most common other sector, with 609 companies (47%).
- 15% were founded in 2020 or later; the median founding year is 2015.
- The most common team size is 11 to 50 employees (47% of companies with a recorded size).
- 3 are unicorns, valued at $1 billion or more.
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 1,286| Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| Prolific Machines | Prolific Machines develops light-controlled gene expression systems for producing therapeutics. | Artificial intelligence | Emeryville | Series B | $50.0M | 2026-10-14 | $147.0M | SOSV, Mayfield Fund, SOSV SF & NY (Fka IndieBio) +2 | 51 to 100 | 2020 |
| Multiply Labs | Multiply Labs builds robotic systems that automate biologics manufacturing. | Artificial intelligence | San Francisco | Series B | $75.0M | 2026-10-06 | $97.7M | Y Combinator, Founders Fund, Garage Capital +2 | 11 to 50 | 2016 |
| Tiny Health | Tiny Health offers at-home microbiome testing and health insights for babies, children, adults, and pregnant people. | Biotech | Austin | Series B | $33.0M | 2026-09-29 | $46.0M | TheVentureCity, Next Coast Ventures, Spero Ventures +2 | 11 to 50 | 2020 |
| UltraSight | UltraSight applies machine learning to ultrasound to support more accurate and timely clinical decisions. | Health care | Cambridge | Series B | $24.0M | 2026-09-23 | $39.0M | Yozma Group | 11 to 50 | 2018 |
| Evvy | Evvy offers an AI-driven precision medicine platform focused on women's health. | Artificial intelligence | New York | Series B | $40.0M | 2026-09-15 | $59.0M | General Catalyst, BoxGroup, Left Lane Capital +2 | 11 to 50 | 2021 |
| Vibronix | Vibronix develops optical and acoustic imaging and sensing technology for surgical guidance and diagnosis. | Artificial intelligence | West Lafayette | Series B | $14.9M | 2026-09-14 | $31.0M | National Science Foundation, Frees Fund, Founder H Fund +1 | 11 to 50 | 2013 |
| Moonwalk Biosciences | Moonwalk Biosciences develops precision epigenetic medications through its genomic medicine platform. | Artificial intelligence | South San Francisco | Series B | $70.0M | 2026-09-08 | $127.0M | Google Ventures, Khosla Ventures, ARCH Venture Partners +2 | 11 to 50 | 2022 |
| Superluminal Medicines | Superluminal Medicines develops small-molecule therapeutics by combining AI, biology, and chemistry. | Artificial intelligence | Boston | Series B | $65.5M | 2026-09-03 | $223.5M | Insight Partners, RA Capital Management, NVentures | 11 to 50 | 2022 |
| David | David makes high-protein, low-calorie foods that support muscle growth and fat reduction. | Health care | New York | Series B | $250.0M | 2026-09-02 | $335.0M | Valor Siren Ventures | 101 to 250 | 2023 |
| N-Power Medicine | N-Power Medicine is a biotechnology company that uses AI to offer clinical research and drug development services. | Artificial intelligence | Redwood City | Series B | $32.0M | 2026-09-01 | $104.0M | Merck Global Health Innovation Fund | 101 to 250 | 2021 |
| Faro AI | Faro AI develops software that automates clinical workflows and assists with clinical trial design. | Artificial intelligence | San Diego | Series B | $37.3M | 2026-08-26 | $72.3M | General Catalyst, Polaris Partners, Zetta Venture Partners +2 | 11 to 50 | 2019 |
| Arintra | Arintra provides AI software that helps enterprises detect and prevent revenue loss. | Artificial intelligence | Austin | Series B | $25.0M | 2026-08-21 | $46.4M | Y Combinator, Surge, TEN13 | 11 to 50 | 2020 |
| Simnova | Simnova Biotherapeutics develops CAR-based cell therapies for treating cancer. | Biotech | Cambridge | Series B | $59.3M | 2026-08-18 | $87.2M | Oriza Seed Capital (Oriza Yuandian), Youshan Capital, PagodaTree Partners +1 | 51 to 100 | 2019 |
| InduPro | InduPro develops proximity-based protein therapeutics that modulate cell-surface protein interactions to treat disease. | Biotech | Seattle | Series B | $77.0M | 2026-08-12 | $162.0M | Euclidean Capital, The Column Group, Vida Ventures +1 | 51 to 100 | 2022 |
| Flagler Health | Flagler Health recommends treatment strategies to physicians using patient data and artificial intelligence. | Artificial intelligence | New York | Series B | $50.0M | 2026-08-11 | $58.5M | MassChallenge | 11 to 50 | 2023 |
| Aureka Biotechnologies | Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. | Artificial intelligence | Laguna Hills | Series B | $100.0M | 2026-08-10 | $168.4M | K2VC, NRL Capital | 11 to 50 | 2023 |
| Theradaptive | Theradaptive develops protein therapeutics for spine, orthopedics, and targeted immuno-oncology. | Biotech | Frederick | Series B | $36.2M | 2026-08-04 | $71.0M | Maryland Stem Cell Research Fund (MSCRF) | 11 to 50 | 2016 |
| Wellinks (formerly Convexity Scientific) | Wellinks develops wearable health technology to improve clinical outcomes for patients. | Health care | New Haven | Series B | $10.0M | 2026-08-04 | $52.6M | Connecticut Innovations, Stonehenge Capital, 5Y Capital +2 | 11 to 50 | 2014 |
| Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| Bunkerhill Health | Bunkerhill Health develops AI agents that enhance clinical and operational teams within health systems. | Artificial intelligence | Palo Alto | Series B | $25.0M | 2026-07-16 | $55.0M | Y Combinator, SciFi VC, Pacific 8 Ventures | 11 to 50 | 2022 |
| Kuehnle Agrosystems | Kuehnle Agrosystems develops plant-based systems to produce biologically active compounds through biotech research. | Biotech | Honolulu | Series B | $3.0M | 2026-07-06 | $11.8M | S2G Investments, Cavallo Ventures, Aqua Spark +2 | 1 to 10 | 2007 |
| Materna Medical | Materna Medical develops medical devices that help women protect and restore their pelvic health. | Health care | Mountain View | Series B | $5.0M | 2026-07-01 | $62.6M | Golden Seeds, Band of Angels, Wavemaker 360 +2 | 11 to 50 | 2010 |
| xCures | xCures aggregates, organizes, and structures electronic medical records across multiple diseases and data types. | Artificial intelligence | Oakland | Series B | $46.0M | 2026-06-24 | $59.0M | Metaplanet, Wavemaker 360, Portfolia +2 | 11 to 50 | 2018 |
| Cour Pharmaceuticals Development | Cour Pharmaceuticals Development develops nanoparticle technology to reset immune systems in multiple sclerosis patients. | Biotech | Skokie | Series B | $50.0M | 2026-06-18 | $185.5M | Alpha Wave Global, Bristol-Myers Squibb, Alpha Wave Ventures +2 | 51 to 100 | 2015 |
| California Naturals | California Naturals sells clean, safe, natural personal care goods at affordable prices. | Health care | Los Angeles | Series B | $21.0M | 2026-06-03 | $25.0M | L Catterton, Elizabeth Street Ventures, Midnight Venture Partners +2 | 1 to 10 | 2023 |
| Triomics | Triomics matches patients to clinical trials using generative AI technology. | Artificial intelligence | San Francisco | Series B | $22.0M | 2026-05-27 | $37.1M | Y Combinator, Lightspeed Venture Partners, General Catalyst +2 | 51 to 100 | 2021 |
| 9amHealth | 9amHealth offers a simplified approach to whole body health, including weight loss and diabetes management. | Health care | Encinitas | Series B | $26.0M | 2026-05-12 | $55.2M | Founders Fund, Speedinvest, StartUp Health +2 | 251 to 500 | 2021 |
| LTZ Therapeutics | LTZ Therapeutics develops novel immunotherapies for cancer and other diseases with unmet clinical needs. | Biotech | San Francisco | Series B | $38.0M | 2026-05-06 | $125.0M | Qiming Venture Partners, Shunwei Capital, K2VC +1 | 11 to 50 | 2022 |
| Courier Health | Courier Health develops a patient relationship management platform for life sciences and biopharma companies. | Health care | New York | Series B | $50.0M | 2026-04-22 | $70.5M | Norwest, Work-Bench | 101 to 250 | 2021 |
| Kytopen | Kytopen develops genome engineering platforms for cell therapy research and manufacturing. | Biotech | Cambridge | Series B | $1.6M | 2026-04-07 | $39.1M | National Science Foundation, MassVentures, Alexandria Venture Investments +1 | 11 to 50 | 2017 |
Table 1. Health care startups that raised Series B in the United States: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 1,286.
Largest rounds
Last 12 months| # | Company | What they do | Sector | City | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | David | David makes high-protein, low-calorie foods that support muscle growth and fat reduction. | Health care | New York | Series B | $250.0M | 2026-09-02 | $335.0M | Valor Siren Ventures | 101 to 250 | 2023 |
| 2 | Mirador Therapeutics | Mirador Therapeutics develops precision medicines for immune-mediated diseases. | Biotech | San Diego | Series B | $250.0M | 2026-01-12 | $730.0M | OrbiMed, Fidelity, ARCH Venture Partners +1 | 11 to 50 | 2024 |
| 3 | Qualified Health | Qualified Health develops AI tools that support clinical decisions and patient care management. | Artificial intelligence | San Carlos | Series B | $125.0M | 2026-03-25 | $155.0M | SignalFire, Flare Capital Partners, Town Hall Ventures +1 | 51 to 100 | 2023 |
| 4 | Diagonal Therapeutics | Diagonal Therapeutics develops targeted therapies for cancer and genetic diseases. | Biotech | Watertown | Series B | $125.0M | 2026-01-08 | $253.0M | Lightspeed Venture Partners, RA Capital Management, Atlas Venture +1 | 11 to 50 | 2022 |
| 5 | Claris Biotherapeutics | Claris Biotherapeutics develops biologic therapies for corneal diseases and ocular surface disorders. | Biotech | Jersey City | Series B | $118.0M | 2026-07-28 | $225.1M | RA Capital Management, Novo Holdings, Janus Henderson Investors +1 | 1 to 10 | 2018 |
| 6 | Sanegene Bio | Sanegene Bio develops an RNAi drug discovery platform aimed at unmet clinical needs. | Biotech | Woburn | Series B | $110.0M | 2025-12-08 | $240.0M | Shenzhen Capital Group, Qiming Venture Partners, Northern Light Venture Capital +1 | 51 to 100 | 2021 |
| 7 | Aureka Biotechnologies | Aureka Biotechnologies uses AI to discover protein therapeutics and antibody treatments. | Artificial intelligence | Laguna Hills | Series B | $100.0M | 2026-08-10 | $168.4M | K2VC, NRL Capital | 11 to 50 | 2023 |
| 8 | Ambrosia Biosciences | Ambrosia Biosciences provides drug development services for small molecule therapies targeting obesity and metabolic disorders. | Biotech | Boulder | Series B | $100.0M | 2026-03-31 | $141.0M | Boulder Ventures, Biotechnology Value Fund | 11 to 50 | 2024 |
| 9 | BlossomHill Therapeutics | BlossomHill Therapeutics is a biopharmaceutical company focused on oncology and autoimmune disorders. | Biotech | San Diego | Series B | $84.0M | 2025-12-10 | $257.0M | OrbiMed, Cormorant Asset Management, Vivo Capital +2 | 11 to 50 | 2020 |
| 10 | Apella Technology | Apella Technology is an AI company that applies modern engineering to improve surgical procedures. | Artificial intelligence | Oakland | Series B | $80.0M | 2026-01-07 | $104.0M | Operator Partners, Upside Partnership, Casdin Capital +1 | 51 to 100 | 2019 |
Table 2. Health care startups that raised Series B in the United States: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | Alumni Ventures | Angel group | Manchester, United States | 16 | 1% | 2 | Benepass, Sorcero |
| 2 | General Catalyst | Venture capital firm | San Francisco, United States | 13 | 1% | 4 | Evvy, Faro AI, Triomics |
| 3 | RA Capital Management | Startup incubator | Boston, United States | 13 | 1% | 3 | Superluminal Medicines, Claris Biotherapeutics, Diagonal Therapeutics |
| 4 | Y Combinator | Startup accelerator | Mountain View, United States | 12 | 1% | 6 | Multiply Labs, Arintra, Bunkerhill Health |
| 5 | National Science Foundation | Entrepreneurship program | Alexandria, United States | 12 | 1% | 4 | Vibronix, Kytopen, BreezeBio |
| 6 | OrbiMed | Private equity firm | New York, United States | 11 | 1% | 2 | Mirador Therapeutics, BlossomHill Therapeutics |
| 7 | Andreessen Horowitz | Venture capital firm | Menlo Park, United States | 11 | 1% | ||
| 8 | Google Ventures | Corporate venture arm | San Francisco, United States | 10 | 1% | 1 | Moonwalk Biosciences |
| 9 | F-Prime | Venture capital firm | Cambridge, United States | 9 | 1% | 1 | Nocion Therapeutics |
| 10 | 8VC | Venture capital firm | Austin, United States | 9 | 1% | 1 | Ritten |
| 11 | ARCH Venture Partners | Venture capital firm | Chicago, United States | 8 | 1% | 2 | Moonwalk Biosciences, Mirador Therapeutics |
| 12 | Alexandria Venture Investments | Venture capital firm | Pasadena, United States | 8 | 1% | 1 | Kytopen |
| 13 | Founders Fund | Venture capital firm | San Francisco, United States | 7 | 1% | 2 | Multiply Labs, 9amHealth |
| 14 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 7 | 1% | 2 | Cour Pharmaceuticals Development, Precede Biosciences |
| 15 | Flare Capital Partners | Venture capital firm | Boston, United States | 7 | 1% | 1 | Qualified Health |
Table 3. Health care startups that raised Series B in the United States: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Biotech | 609 | 47% | $47.7B |
| Software | 289 | 22% | $13.7B |
| Artificial intelligence | 110 | 9% | $8.0B |
| Hardware | 62 | 5% | $2.0B |
| Fintech | 45 | 3% | $2.3B |
| Commerce | 37 | 3% | $1.3B |
| Education | 13 | 1% | $555.1M |
| Cybersecurity | 6 | 0% | $195.3M |
Table 4. Health care startups that raised Series B in the United States by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 1,286 | 100% | $23.0M |
Table 5. Health care startups that raised Series B in the United States by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| San Francisco | 88 | 7% |
| New York | 87 | 7% |
| Cambridge | 75 | 6% |
| Boston | 61 | 5% |
| San Diego | 60 | 5% |
| Seattle | 34 | 3% |
| Palo Alto | 25 | 2% |
| Los Angeles | 22 | 2% |
| Austin | 20 | 2% |
| Houston | 20 | 2% |
| Waltham | 16 | 1% |
| San Jose | 16 | 1% |
Table 6. Health care startups that raised Series B in the United States by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 1% | $41.9M |
| October 2026 | 8 | 6% | $685.8M |
| September 2026 | 13 | 10% | $822.9M |
| August 2026 | 14 | 10% | $700.6M |
| July 2026 | 12 | 9% | $414.4M |
| June 2026 | 16 | 12% | $1.3B |
| May 2026 | 5 | 4% | $234.5M |
| April 2026 | 8 | 6% | $384.1M |
| March 2026 | 9 | 7% | $545.5M |
| February 2026 | 7 | 5% | $334.0M |
| January 2026 | 20 | 15% | $1.1B |
| December 2025 | 17 | 13% | $833.8M |
| November 2025 | 4 | 3% | $274.7M |
Table 7. Health care startups that raised Series B in the United States: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 113 | 9% | $6.5B |
| 2025 | 139 | 11% | $6.8B |
| 2024 | 117 | 9% | $5.2B |
| 2023 | 101 | 8% | $3.9B |
| 2022 | 104 | 8% | $3.5B |
| 2021 | 141 | 11% | $6.4B |
Table 8. Health care startups that raised Series B in the United States by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 30 | 2% |
| 2020 to 2022 | 156 | 12% |
| 2015 to 2019 | 456 | 36% |
| 2010 to 2014 | 294 | 23% |
| Before 2010 | 345 | 27% |
Table 9. Health care startups that raised Series B in the United States by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 224 | 18% |
| 11 to 50 | 593 | 47% |
| 51 to 100 | 228 | 18% |
| 101 to 250 | 136 | 11% |
| 251 to 500 | 43 | 3% |
| 501 to 1,000 | 22 | 2% |
| 1,001 to 5,000 | 11 | 1% |
| 5,001 to 10,000 | 2 | 0% |
| 10,001 or more | 8 | 1% |
Table 10. Health care startups that raised Series B in the United States by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Health care is one of its sectors and its most recent funding round is Series B and its headquarters is in the United States. On 16 November 2026 that is 1,286 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 1,286 rows: 121 have no round amount, 0 no city and 123 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many health care startups in the United States whose last round is Series B are on the list?
- 1,286, in the file dated 16 November 2026. 134 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 1,286 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.